The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Chang Y, Keramatnia F, Ghate PS, Nishiguchi G, et al. Blood 2023 May 12:blood.2022017813. doi: 10.1182/blood.2022017813.

Read + Share

Amedeo Smart

Independent Medical Education

Chang Y, Keramatnia F, Ghate PS, Nishiguchi G, et al. The orally bioavailable GSPT1/2 degrader SJ6986 exhibits in vivo efficacy in acute lymphoblastic leukemia. Blood 2023 May 12:blood.2022017813. doi: 10.1182/blood.2022017813.
PMID: 37172201